Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 17/20 | 0.64 |
| ▸ | TACR1 | P25103 | 6/20 | 0.64 |
| ▸ | TACR3 | P29371 | 5/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6668994 | 1.00 | TACR2 (0.64) | TACR2TACR1TACR3 | |
| SCHEMBL7666225 | 0.91 | TACR2 (0.54) | TACR2TACR1TACR3 | |
| SCHEMBL4255229 | 0.89 | TACR2 (0.52) | TACR2TACR1TACR3 | |
| SCHEMBL756153 | 0.89 | TACR2 (0.61) | TACR2TACR1TACR3 | |
| SCHEMBL6002109 | 0.88 | TACR2 (0.59) | TACR2TACR1TACR3 | |
| SCHEMBL4256214 | 0.88 | TACR2 (0.59) | TACR2TACR1TACR3 | |
| SCHEMBL5015402 | 0.87 | TACR2 (0.71) | TACR2TACR1TACR3 | |
| SCHEMBL7668591 | 0.87 | TACR2 (0.51) | TACR2TACR1TACR3 | |
| SCHEMBL4257601 | 0.86 | TACR2 (0.72) | TACR2TACR1TACR3 | |
| Acetic Acid SCHEMBL7692910 | 0.86 | TACR2 (0.57) | TACR2TACR1TACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1954678-B1 | NOVEL NK1 AND NK2 ANTAGONISTS | ABBOTT PRODUCTS GMBH (DE) | 2012-03-21 | — | — | EP | disclosed |
| US-6821973-B2 | ANTAGONIZE THE PHARMACOLOGICAL ACTIONS OF THE ENDOGENOUS NEUROPEPTIDE TACHYKININS KNOWN AS NEUROKININS | ASTRAZENECA AB (SE) | 2004-11-23 | — | — | US | disclosed |
| EP-1169302-B1 | N-(2-PHENYL-4-AMINO-BUTYL)-1-NAPHTHAMIDES AS NEUROKININ-1 RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2004-09-29 | — | — | EP | disclosed |
| US-20040106610-A1 | Compounds | BERNSTEIN PETER ROBERT (US) | 2004-06-03 | — | — | US | disclosed |
| US-6586432-B2 | Peptide neurotransmitter suppressors such as N-((-2-(3,4-dichlorophenyl)-4-morholino)butyl)-N-methyl-2-methoxy-3-cyano-1 -naphthamide, used for prophylaxis of arthritis, pain, alzheimer's disease, schizophrenia, edema, rhinitis or asthma | ASTRAZENELA AB (SE) | 2003-07-01 | — | — | US | disclosed |
| US-20030092713-A1 | Neurokinin-1 receptor antagonists | BERNSTEIN PETER ROBERT (US) | 2003-05-15 | — | — | US | disclosed |
| US-6476077-B1 | N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists | ASTRAZENECA AB (SE) | 2002-11-05 | — | — | US | disclosed |
| US-6365602-B1 | FOR THERAPY OF DEPRESSION, ANXIETY, ASTHMA, PAIN, INFLAMMATION, URINARY INCONTINENCE AND OTHER DISEASE CONDITIONS | ASTRA ZENECA AB (SE) | 2002-04-02 | — | — | US | disclosed |
| EP-1169302-A1 | N-(2-PHENYL-4-AMINO-BUTYL)-1-NAPHTHAMIDES AS NEUROKININ-1 RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2002-01-09 | — | — | EP | disclosed |
| EP-1097137-A1 | N-SUBSTITUTED NAPHTHALENE CARBOXAMIDES AS NEUROKININ-RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2001-05-09 | — | — | EP | disclosed |
| WO-2000059873-A1 | N-(2-PHENYL-4-AMINO-BUTYL)-1-NAPHTHAMIDES AS NEUROKININ-1 RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2000-10-12 | — | — | WO | disclosed |
| WO-2000002859-A1 | N-SUBSTITUTED NAPHTHALENE CARBOXAMIDES AS NEUROKININ-RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2000-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106610-A1 | Compounds | NR2C2, NR0B2, NR5A2 | TACR2 1493/4885TACR1 2195/4885TACR3 1912/4885 |
| US-20030092713-A1 | Neurokinin-1 receptor antagonists | NTSR2, NTSR1, CRHR2 | TACR2 5/4885TACR1 6/4885TACR3 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.